InvestorsHub Logo
icon url

Omar8

03/12/21 7:53 PM

#13863 RE: yman #13862

yman......






This is from 2010....before that 50 cents.....who was talking up the stuff ? Who do you believe DP and his opinion or this article ? Notice the company doesn't have this on their site anymore ? If it weren't for me saving it, those others would be telling whatever they want and nothing to counter it.

They didnt deliver..plain and simple....there is more than this....other updates that sounded promising too

People back on other boards were making up production numbers and dreaming hard. When over time it didn't happen, the price would eventually suffer. Those believing the big talk and held got screwed. Some of them, I believe want to blame some evil story because they don't want to admit what I am saying now.




Local company develops new petri dish
Published: Mon, June 7, 2010 @ 12:00 a.m.

By GRACE WYLER
gwyler@vindy.com

hubbard

A local biotechnology company has started production on a new type of petri dish that it says has the potential to shape the future of laboratory testing.

Nanologix, a small company tucked behind the Emerald Diner at 843 North Main St., finished renovations of its production facility earlier this year and has started to manufacture its BioNanoPore, or BNP, test kits. The company expects to begin full-scale production “any day now,” said chief executive Bret Barnhizer.

The patented BNP technology, developed at the company’s research lab in Cincinnati, promises to confirm the presence of microorganisms such as bacteria and viruses in a fraction of the time needed by standard petri dishes, Barnhizer said.

“We’re looking forward to making a big impact in the market,” he said. “I don’t think we are going to be a small company for very long.”

The Hubbard site, a former bath and cabinet shop, has room for 56 production machines with the capacity to produce 350,000 test kits per day.

The company has only installed eight machines so far, but more are on the way, said Barnhizer.

Nanologix has 10 employees working at its Hubbard facility, and plans to hire about 10 more by the end of the year, Barnhizer said. At full capacity, the site could employ 75-100 workers, he said.

“Our goal is high-volume production,” Barnhizer said.

Barnhizer expects that, as Nanologix’s technology becomes better known, the company will be able to corner a significant portion of the laboratory testing market.

Unlike standard petri dishes, the BNP product puts the microorganism on a membrane that is impermeable to the cells. The nutrient solution below and above the membrane allow the organism to grow.

Instead of waiting for microorganism growth to become visible in the petri dish, the membrane is put on a staining solution that highlights growth before it could be seen in a standard petri dish.

“We’re the next generation of petri dishes,” Barnhizer said. “We are going to make it so people depend on petri dishes.”

The technology has been successfully tested by several third party laboratories, Barnhizer said.

The Battelle Memorial Institute in Columbus, an applied science and technology company, published a study last year that shows that BNP kits showed results in significantly less time than traditional methods in tests for anthrax and bubonic plagues. According to the study, the BNP anthrax tests took only six hours, while traditional tests needed 24. And the BNP tests for bubonic plague cut the traditional testing time — 48 hours — in half.

The potential for Nanologix’s rapid detection technology is huge, Barnhizer said. For example, if doctors could detect harmful pathogens — such as staphylococcus, which causes staph infections, or Group B streptococcus, a harmful bacteria found in 30 percent of reproductive-age women — in a shorter amount of time, they would not have to use broad-spectrum antibiotics while waiting for test results. This would presumably lessen the existence of antibiotic-resistent bacteria, Barnhizer added.

“This is pretty much the biggest thing to happen to the petri dish,” Barnhizer said. “I won’t say it’s as big as penicillin, but its huge.”
icon url

Omar8

03/12/21 8:00 PM

#13864 RE: yman #13862

Yman..........



Here follow the updates and and compare to share price.......it tells a story.....there was plenty being put out back then, to support a $1 price if things had come to be...when stuff kept lingering like it seems like this virus stuff is doing now...people will give up.......or you can believe that evil story that did it to the share price, your choice.







Some news through the earlier years(2009-2013)




• August 18, 2013:
Dr Jonathan Faro of the UTHSC at Houston presented two posters at the IDSOG meeting in Albuquerque showing the results of tests with NanoLogix BNF and new Multiwell N-Assay diagnostics. The N-Assay delivered 30 minute results for detection and identification of Group B Streptococcus (GBS) while the BNF provided detection, identification, and determination of sensitivity to clindamycin antibiotic in 6 - 6.5 hours. Both tests are significantly faster than the standard tests in use, which take 48-72 hours for the same results. The significance of the results and impact upon screening for GBS in pregnancies, and potentially in the elderly and immuno-compromised patients of all ages, is tremendous.
1. FC-Fragment.pdf
2. Clinda.pdf

• August 06, 2013:
NanoLogix Inc. Report on technologies
To assist in the commercialization, production, and marketing of NanoLogix BNP, N-Assay, BNF, and..

• June 21, 2013:
NanoLogix Inc. Report on technologies

June 21, 2013 Video instructional update for use of BNP kits

• Jun 11, 2013: Nanologix® News: US EPA and NanoLogix to Extend Agreement to 2015 Read more>>>

• April 30, 2013:
NanoLogix Inc. Report on technologies
The past fifteen months have been highly successful for NanoLogix as it continues to develop new products and new markets. In that time, the company has advanced in a number of important areas, including development of new technologies, increasing sales and customer bases, and garnering substantial recognition in published research on NanoLogix products and techniques. We are excited by these developments and by additional new opportunities.

New Technologies

The technological developments at NanoLogix are revolutionary. Besides improving on existing BNP and BNF products and protocols, the Company has gained great success in the market for its Extended-Life Petri dishes and BNP diagnostic kits that are vacuum-packed in gas charged FlatPacks. The FlatPack technology – exclusively licensed by NanoLogix – represents a major breakthrough in supply-chain management for these products. Users of FlatPack-packaged Petri dishes can potentially achieve significant cost savings and supply chain efficiencies over traditional Petri dish supply because select-media FlatPack plates do not require refrigeration, have a significantly reduced rate of loss in shipment and storage, and have a shelf life far beyond that of traditional Petri dishes. The company is currently selling Extended-Life Petri dishes and BNP diagnostic kits that are vacuum-packed in gas-charged FlatPacks and made in various common nutrient media configurations. Customers to date include independent laboratories and hospital laboratories, defense contractors and Federal agencies. NanoLogix products are at present being used on six classified Federal government projects, with expanded use expected this year. Those projects are funded by the United States Department of Defense and the Environmental Protection Agency.
In the past year we and our collaborators in research and development have made significant refinements to our existing technologies and have also developed one additional rapid test. The new test has been named the N-Assay. The N-Assay is a unique ELISA multiwell machine-readable assay that provides results for bacteria identification and antibiotic sensitivity in less than one hour with high sensitivity and specificity. Indications to date are that the N-Assay will provide rapid results for any bacteria for which an antibody exists. We at NanoLogix and the researchers using the N-Assay are very excited at this new development. The N-Assay is projected to provide a premier platform for Point-of–Care rapid diagnostics. N-Assay patent filings were made in 2013. It is projected that the N-Assay will be more suitable for use in some developed areas than our BNF identification technology, but not in other areas or regions that are less developed.

Scholarship and Research on NanoLogix Technologies

In December 2012 a paper was published in the Journal of Microbial and BioChemical Technology detailing preliminary results using the company’s BNP technology for detection of live Tuberculosis through culture. Those results were obtained in five days, compared to weeks with standard culture methods. http://www.omicsonline.org/1948-5948/pdfdownload.php?download=JMBT-04-147.pdf In January of 2013 the final results of a 356 patient clinical study by researchers at the University of Texas Health Science Center at Houston were published in the Journal of Infectious Diseases in Obstetrics and Gynecology detailing the results obtained with NanoLogix’s BNF technology for rapid detection of Group B Streptococcus in pregnant patients. http://www.hindawi.com/journals/idog/2013/367935/

New License and Patents

The company has been recently granted a patent for its BNP technology in Japan, its BNC technology in China, and has indications that it will soon receive a grant of patent in the EU for BNP. Patents are pending for BNP in the US, China, Russia, India, Brazil and the EU. Patents for BNF technology are pending in the US, China, the EU, Japan, India and Brazil. A US patent was granted in April 2013 for the FlatPack® packaging technology, to which NanoLogix has an exclusive license. The FlatPack® technology has been pivotal to the sales of filled Petri plates by the company, with extraordinary increases in shelf life, durability of product during shipping, and numerous other advantages over all competitors’ similar products. We have exhibited our BNF and BNP and licensed FlatPack® Petri technologies at multiple events: the American Society for Microbiology (ASM) BioDefense and Emerging Diseases Meeting and the Food Safety Summit, both in Washington, D.C., and at the ASM Annual Meeting in San Francisco
Marketing

In 2013, NanoLogix contracted with a team of independent marketing specialists to promote the Company’s products to key opinion leaders (KOLs) and executives in multiple health, industrial, pharmaceutical and food sectors. The marketing team is composed of current or former directors and managers of two national and international pharmaceutical corporations. This alliance continues the transition of the Company from a primary focus on research and development to one of production and marketing. There will be a continued science emphasis upon product Quality Assurance and Quality Control and also water quality test development with the US EPA. This new focus is resulting in a reallocation of resources with a heavy emphasis upon increased high level marketing on multiple fronts.

Financial Matters

As of 1 April 2013, the company has 122,679,679 shares outstanding of an authorized limit of 200,000,000 shares. Our current monthly operations costs are approximately $42,000. That amount includes the costs of NanoLogix-funded studies, other tests of our products by third parties, and new patent applications. NanoLogix is funded by a combination of revenue from increasing sales, loans to the company by its CEO, and a limited number of private placement stock sales, with investors providing funding in exchange for common stock restricted from market sale for one year from date of issuance. The company does not sell shares on the open market. The Company has received a number of inquiries regarding share compensation to Directors and sales of those shares. All Directors are compensated for their contribution to the Company by payment in restricted shares. The Directors are closely involved with the business of the Company, communicate with the CEO on a daily or near-daily basis, and participate in board of director meetings regularly. All Directors have been personally involved in assisting financially with the needs of the Company, both through personal direct investment and also through facilitation of private placement investment from friends, family, colleagues, and associates who approached the Directors. The Directors have been responsible in this way for the overwhelming majority of funds raised to run the company over the past five years, amounting to roughly 92% of funds raised. To date, none of the shares paid to the Directors, including the CEO, have been sold. All of the share certificates issued to the members of the Board of Directors are still classed as restricted shares and can only be sold under strict SEC Rule 144 guidelines. In summation, there has been no realized monetary gain from the shares received as compensation by the Board of Directors *** the shares cannot be used as collateral for loans, nor can they be classed as a liquid asset. The Board of Directors is independent, with the directors employed individually in professions completely unrelated to the business of NanoLogix. Their work as Directors of the Company has been based upon what they believe to be the potential of the Company, not for any immediate capital gain.

In late 2012 and early 2013 Nanologix was approached separately by two multibillion dollar corporations regarding business association, development and product usage. NanoLogix has signed Mutual Confidentiality Agreements with both corporations.

• April 05, 2013:

NanoLogix plans to begin marketing this summer of their new N-Assay Multiwell Diagnostic test. The N-Assay is a machine-readable test that will be available in an assortment of size configurations for detection and identification of a variety of bacteria. Tests to date have provided consistent results in as little as 30 minutes with both high sensitivity and specificity.

• April 02, 2013:

NanoLogix has been informed that they have been granted a patent in Japan for the Company's BNP detection technology. This is the first granted patent of seven patents pending for BNP throughout the world.

• Jan 22, 2013: NanoLogix Inc is pleased to announce that the results of the University of Texas Health Science Center - Houston (UTHSC - Houston) Clinical Study utilizing NanoLogix's BNF technology to detect and identify Group B Streptococcus in pregnant patients have been accepted for publication in a noted peer-reviewed journal. The 352-patient Clinical Study was performed from March 2011 through May 2012 at Memorial Hermann Hospital in Houston. In the study, times for detection and identification of GBS were reduced from 48-72 hours to 4-6 hours. In accordance with journal protocols and preservation of pre-release confidentiality, further details will be released upon publication.

June 11, 2013

Nanologix® News: US EPA and NanoLogix to Extend Agreement to 2015 Read more>>>

NanoLogix Clean Room
Apr 30, 2013

Nanologix® News:NanoLogix to Exhibit at Food Safety Summit in Baltimore and American Society for Microbiology Annual Meeting in Denver. Read more>>>

Apr 2, 2013
Nanologix® News:NanoLogix has been informed that they have been granted a patent in Japan for the Company's BNP detection technology. This is the first granted patent of seven patents pending for BNP throughout the world..

Mar 13, 2013
Nanologix® News:UTHealth researchers say more rapid test for Group B strep successful. Read more>>>

Feb 20, 2013
Nanologix® News: NanoLogix Bacteria Detection Plates Break Longevity Records Using Anthrax as Reference Bacteria. Read more>>>

Jan 11, 2013
Nanologix® News: Third-party results for ongoing agar room temperature (RT) testing at 4 months+. Current NanoLogix internal lab results for RT testing have passed the 9-month point, with no degradation of the agar. Read more>>>

Jun 19, 2013
This Video contains a short description of protocol for users of NanoLogix BNP bacteria/mold detection kits. You will see detection of an eColi O157 H7 lab sample after 30 minutes of incubationp>

Jun 11, 2013
Nanologix® News: US EPA and NanoLogix to Extend Agreement to 2015

Apr 30, 2013
Nanologix® News: NanoLogix to Exhibit at Food Safety Summit in Baltimore and American Society for Microbiology Annual Meeting in Denver.

March 13, 2013
UTHealth researchers say more rapid test for Group B strep successful

Feb 20, 2013
NanoLogix Bacteria Detection Plates Break Longevity Records Using Anthrax as Reference Bacteria

Jan 11, 2013
Nanologix® News: nanologix packing systemThird-party results for ongoing agar room temperature (RT) testing at 4 months+. Current NanoLogix internal lab results for RT testing have passed the 9-month point, with no degradation of the agar.

February 25th - 27th, 2013: 2013 ASM BioDefense and Emerging Diseases Research Meeting


August 18, 2013

Dr Jonathan Faro of the UTHSC at Houston presented two posters at the IDSOG meeting in Albuquerque showing the results of tests with NanoLogix BNF and new Multiwell N-Assay diagnostics. The N-Assay delivered 30 minute results for detection and identification of Group B Streptococcus (GBS) while the BNF provided detection, identification, and determination of sensitivity to clindamycin antibiotic in 6 - 6.5 hours. Both tests are significantly faster than the standard tests in use, which take 48-72 hours for the same results. The significance of the results and impact upon screening for GBS in pregnancies, and potentially in the elderly and immuno-compromised patients of all ages, is tremendous.
1. FC-Fragment.pdf
2. Clinda.pdf

August 6,2013
NanoLogix Inc. Report on technologies Date: 6 August 2013

April 9, 2013
Patent No.: US 8413800B2 & Patent Date: 9 April 2013

March 13, 2013
UTHealth researchers say more rapid test for Group B strep successful

Feb 20, 2013
NanoLogix Bacteria Detection Plates Break Longevity Records Using Anthrax as Reference Bacteria
________________2013

Jan 22, 2013: NanoLogix Inc is pleased to announce that the results of the University of Texas Health Science Center - Houston (UTHSC - Houston) Clinical Study utilizing NanoLogix's BNF technology to detect and identify Group B Streptococcus in pregnant patients have been accepted for publication in a noted peer-reviewed journal. The 352-patient Clinical Study was performed from March 2011 through May 2012 at Memorial Hermann Hospital in Houston. In the study, times for detection and identification of GBS were reduced from 48-72 hours to 4-6 hours. In accordance with journal protocols and preservation of pre-release confidentiality, further details will be released upon publication.
2012

Nov 9, 2012: NanoLogix Subject of EPA Featured News article, NanoLogix's Cooperative Research and Development Agreement (CRADA) with the US Environmental Protection Agency is covered in an article posted this week on the EPA's internal news site: The article covers current and projected aspects of the CRADA. Focus is on the ongoing joint development efforts of the EPA and NanoLogix related to creation of a comprehensive water quality test kit for use in all ten EPA regions. The current scope of the effort is focused on testing of drinking and source water. Read more
Aug 21, 2012: Hubbard, OH, August 21, 2012 . NanoLogix (OTC Markets: NNLX), a biotechnology innovator in the rapid detection and identification of live-threat bacteria and microorganisms, announces it will begin commercialization of its BNP (BioNanoPore) and BNF (BioNanoFilter) diagnostic kits under FDA 510K-exempt status. The first product to be marketed will be the Petri-based BNP detection kit utilizing TSA media. Other nutrient media will be available by special order. Recently completed independent third-party research has demonstrated BNP diagnostic kits to be two to ten times faster at live bacteria detection than traditional methods. Following the BNP rollout, NanoLogix plans to commercialize its BNF technology, which third-party research documents as 18 to 72 times faster than conventional detection and identification methods. The company also plans to develop customized test kits for particular applications and client partners.
Peer-Reviewed Research Pending Publication The results of two independent third-party research studies using NanoLogix technology have been submitted by their respective organizations to major peer-reviewed medical technology journals for publication. The first submission details the use of NanoLogix BNF test kits and final results of a 356 pregnant-patient Group B Streptococcus (GBS) clinical study at the University of Texas Health Science Center - Houston. This study attained GBS detection, identification and antibiotic-sensitivity results from samples collected in as little as 6 hours, a sharp contrast to traditional laboratory test times of 48-72 hours. One major goal in the study was to ensure the ability to test for antibiotic sensitivity in reduced time from the standard, potentially enabling physicians to rapidly tailor antibiotics to the actual infection involved and reduce the overuse of broad spectrum antibiotics.
Aug 15, 2012: NanoLogix is pleased to announce that the company will begin commercial marketing of its BNP (BioNanoPore) and BNF (BioNanoFilter) diagnostic kits under FDA 510K-exempt status. The first to be marketed will be the BNP sandwiched-membrane petri kit with TSA media. BNP kits with other nutrient media will be available in the near future by special order. Thereafter, NanoLogix plans to expand commercial operations to marketing its BNF technology for ultra-fast identification of specific subject microorganisms. The company plans to introduce commercial applications for commonly tested microorganisms, but will also work to develop client-specific customized test kits for particular applications.
The company will also initiate sales of TSA petri plates. Both BNP and Petri plates will be packaged in the company's proprietary vacuum Flat Packs. In addition, the final results of both the University of Texas Health Science Center.Houston's clinical study for Group B Strep in pregnancies, and a large third-party research and development organization's Tuberculosis laboratory study have been submitted, by each respective institution, to major peer-reviewed medical journals for publication. One paper details the final results of the 356-patient Group B Streptococcus clinical study at the University of Texas Health Science Center in Houston. The other paper features data from the third-party laboratory responsible for using NanoLogix BNP test kits to achieve detection of live Tuberculosis colonies in five days compared to the 21-28 days attainable through normal culturing.
July 9, 2012: University of Texas Health Science Center - Houston clinical study interim results, utilizing NanoLogix diagnostic technology, were presented at the 112th Annual meeting of the American Society for Microbiology in San Francisco from June 16 - 19, 2012. Authors of the research include Jonathan Faro MD, Ph.D, Karen Bishop MS, Gerald Riddle MS, Allan Katz MD, and Sebastian Faro MD. These interim results demonstrate clinical efficacy of NanoLogix technology. The clinical study included a pool of 300 pregnant women, tested for antibiotic sensitivity in the presence of Group B Streptococcus (GBS). --> View presentation poster
July 5, 2012: NanoLogix Announces Vendor Status
The company is pleased to announce it has been selected as a vendor by a multi-billion dollar US research and development corporation. The corporation has notified NanoLogix it intends to use approximately 12,000 units of NanoLogix detection technology for a project beginning in July 2012. This marks the first large sale of NanoLogix technology.
May 21, 2012: Updates to Cleanroom Manufacturing Operation

NanoLogix has recently completed major changes and updates to the cleanroom manufacturing operation. These enhancements have been implemented to optimize product quality and the manufacturing process. A computerized, state of the art, environmental monitoring system designed by LIGHTHOUSE Worldwide Solutions has been installed and is in operation. This system continuously monitors air quality, temperature, humidity, and air pressure on a real-time basis. Our cleanroom air filtration system has been re-designed to maximize the quality of the air within the space. The air filtration system has been upgraded to include 10 high-quality AIRGUARD filters, thus enabling our manufacturing space to operate at a solid ISO 6 level in a static mode as described within ISO 14644-1 Cleanroom Standards.

NanoLogix Clean Room
May 14, 2012: Data Collection Completed for Group B Strep Clinical Study

NanoLogix has reached a milestone with the completion of a 352-patient clinical study focused on rapid detection of Group B Streptococcus in pregnant patients. Conducted at University of Texas Health Science Center in Houston under Jonathan Faro, PhD, MD, the study confirms dramatic improvements in detection, identification, and determination of the antibiotic sensitivity of Group B Streptococcus with results for the entire process in 6 hours or less.

This represents the latest phase in the evolution of NanoLogix technology within the past eighteen months. Revision of testing protocols during that time have led to results significantly faster and more specific than in initial tests done with NanoLogix products in 2010. This clinical study also marks the first time NanoLogix technology has been used with samples from human patients. Clinical studies, as opposed to clinical trials, are limited to research without medical intervention. NanoLogix anticipates the next step to be a clinical trial with medical intervention.

The results of the completed clinical study are being prepared for publication in a major peer-reviewed medical science journal. The information on results of the 352-patient sampling is being submitted to the FDA as a non-invasive diagnostic kit application, with results forwarded to both the Centers for Disease Control and the World Health Organization.

The University of Texas Health Science Center has recently revised its regulations for staff involvement with private companies. In order to comply with this change, Drs. Sebastian Faro and Alan Katz have resigned from the NanoLogix Science Advisory Board. Both Dr. Faro and Dr. Katz will continue to participate in research involving NanoLogix technology.
April 8, 2012: 2012 General Meeting of American Society for Micobiology

Results of use of NanoLogix BNF technology will be presented at the 2012 General Meeting of the American Society for Microbiology in San Francisco, June 16-19, 2012 by Dr. Jonathan Faro of the University of Texas Health Science Center-Houston. Dr. Faro is the lead researcher in the 350-patient Group B Streptococcus clinical study being conducted at UTHSC-Houston. The study has currently passed the 330-patient point.
March 27, 2012: Society for Gynecologic Investigation - 2012 Annual Scientific Meetin

University of Texas Health Science Center GBS research using NanoLogix technology was presented in poster form at the Society for Gynecologic Investigation - 2012 Annual Scientific Meeting, (March 21-24, 2012). Lead physician on the research Dr. Jonathan Faro states, "We were very happy to have had the opportunity to present our poster at the 59th annual scientific meeting of the Society for Gynecologic Investigation in San Diego. This was a terrific opportunity to share our research with other investigators, and we were happy to see that our initial data showing that GBS may be detected in under one hour was well received. There was a genuine interest by several clinicians in this assay, and we hope to provide them with further data in the near future." View the poster here>>
March 2, 2012: NanoLogix has registered to exhibit at the Food Safety Summit, April 17-19 in Washington, DC, (booth # 517).
February 28, 2012: ASM BioDefense and Emerging Diseases Research Meeting

NanoLogix is currently exhibiting at the ASM BioDefense and Emerging Diseases Research Meeting in Washington D.C., February 26-29, 2012. NanoLogix technology, on display at booth # 27, is receiving strong interest.
February 13, 2012 UTHSC Group B Strep Exhibited in Poster Presentation

Group B Strep research from University of Texas Health Science Center presented at the poster session of the Society for Maternal-Fetal Medicine’s 32rd Annual Meeting in Dallas, TX (February 6-11, 2012). View the poster here>>
February 13, 2012: NanoLogix to Exhibit at ASM BioDefense and Emerging Diseases Research Meeting

This month, NanoLogix will exhibit at the ASM BioDefense and Emerging Diseases Research Meeting in Washington D.C., February 26-29, 2012. NanoLogix technology, including BNP and BNF will be on display at booth # 27.
February 9, 2012

Over the past year, major developments at NanoLogix have drawn the attention of food processors, medical and veterinary facilities, universities, major diagnostic kit producers, government agencies, large and small clinics and hospitals, and various labs. Interest in our products continues to grow among both domestic and international entities.

The comprehensive operations summary of 2011, which covers technology advances, partnership collaborations, preparations for FDA approvals, media coverage, financial information and the company’s new R&D laboratory.

Read the full operations summary here>>
January 12, 2012: NanoLogix Joins WHO StopTB Partnership

NanoLogix is pleased to announce it has been accepted as a member to the World Health Organization’s Stop TB Partnership. The organization consists of nearly 1000 partner members who are a collective force that is transforming the fight against TB in more than 100 countries. They include international and technical organizations, government programs, research and funding agencies, foundations, NGOs, civil society and community groups and the private sector. More information on NanoLogix membership in the StopTB Partnership can be found at http://www.stoptb.org/partners/partner_profile2.asp?PID=69342.
2011

June 7, 2011: NanoLogix technology to be used for detection of E. coli strain found in Germany’s outbreak

The company has added the E. coli 0104:H4 to the battery of bacteria being tested with NanoLogix technology by a major U.S. Biodefense contractor. E. coli 0104:H4 has been added in the interest of world health and the company plans to share its results with the appropriate U.S. and international bodies fighting foodborne illnesses.

Since May 2, 2011, E. coli 0104:H4 has killed 23 people and sickened over 2300. So far, officials estimate that the agriculture industry in Spain is losing €200m a week and German famers are losing about €1m a day as a result.
May 31, 2011: The company had a very successful exhibit at the American Society for Microbiology General Meeting in New Orleans last week. Interest was renewed with a Japanese firm and new interest was generated from various parties including the US Navy, US Army, USDA, and the Centers for Disease Control and Prevention (Atlanta).

Based on the success of the ASM and other business building activities, the company will be shipping BNP and BNF kits to the USDA next week for testing and to a major food processing company in a few weeks.

Also this week, the first phase of the University of Texas Health Science Center clinical trial was accepted for publication by a major peer-reviewed journal. The name of the journal will be announced upon publication of the UTHSC paper.
May 23, 2011: The company is exhibiting this week at the 2011 General Meeting of the American Society of Microbiology in New Orleans. The conference runs through May 24th. View the booth display>>
April 15, 2011: NanoLogix is honored to have been chosen as one of three finalistsfor Outstanding Biotech Innovation, in the Cincinnati USA Regional Chamber and CincyTech 2011 Innovation Awards. NanoLogix congratulatesBexion Pharmaceuticalson winning the award for their research on drug development for identification of early indicators of tumor growth.
April 1, 2011: NanoLogix featured in April issue of Medical Laboratory Observer magazine.
February 18, 2011: NanoLogix featured in Lab Manager Magazine "Bacterial culturing for faster detection"
February 3, 2011: NanoLogix Nominated for Cincinnati USA Regional Chamber and CincyTech Innovation Award

NanoLogix has been nominated for a Cincinnati USA Innovation Award in the category of: Outstanding Biotech Innovation – Small Business – a company with fewer than 50 employees that has achieved a significant milestone in the life sciences, including but not limited to drug therapeutics, medical devices, medical imaging and pharmacogenomics.

The goal of the program, which is organized by the Cincinnati USA Regional Chamber, the Business Courier, and CincyTech, is to recognize innovative products and services at all levels of the business community that are aimed at spurring the development of new ideas as an economic engine. NanoLogix was nominated for the award by Carol Frankenstein, President of BIOStart in Cincinnati.
February 3, 2011: UT Houston Clinical Trial Update

Jonathan Faro, MD, Ph.D, UTHSC-Houston Ob/Gyn Chief Resident and head of the study stated: "Regarding active studies with GBS utililizing NanoLogix technology, we at UT Houston have been very pleased with our initial results. We recently submitted an abstract of the first phase results to the American Society For Microbiology (ASM) and anticipate presenting our data at the annual ASM conference in New Orleans this May. If accepted, this presentation will highlight the first phase of the project which focuses on development of the assay and will form the foundation for the 300-patient clinical trial which is underway."
January 27, 2011: NanoLogix featured in hiVelocity Media
2010

November 24, 2010: Internal Update, Engaged Services of major defense organization

NanoLogix has engaged the services of a major biodefense and biomedical research corporation to evaluate the NanoLogix BNF technology for detection and identification of six types of bacteria. This series of tests will include Vibrio cholerae (Cholera). The study is being funded by NanoLogix
August 25, 2010: New Patent Granted

The company has been issued U.S. patent #7,781,159 for its invention of a method and device for the rapid detection, enumeration and identification of microorganisms. This is one of two foundational patents granted this year for our BioNano technologies.
August, 20, 2010: NanoLogix featured in this month’s issue of Medical Design Technology magazine, Speeding Up Petri Dish Diagnostics. “Petri dish technology is used around the world and the sandwiched-membrane BioNanoPore (BNP) test kits hold the potential to change diagnostics across the board."
August, 20, 2010: BNF technology highlighted in ADVANCE

NanoLogix BNF technology highlighted in ADVANCE for Administrators of the Laboratory, NanoLogix and UT Medical Center Shorten Wait Times for Group-B Streptococcus Tests. “ NanoLogix Inc. offers its BNF technology in controlled testing at the University of Texas-Texas Medical Center in Houston for the bacteria Group B Streptococcus (GBS) in pregnant women.
August 9, 2010: This week, CEO Bret Barnhizer travels to Europe for meetings. Later this month, he and Dr. Sergey Gazenko will travel to Japan.
June 30, 2010: NanoLogix has filed and received medical device registration approval from the U.S. FDA for their BNP™ BNF™ and BNC™ test kits. Registration number: 3005553828.
June 24, 2010: The Company has received the remaining 10 machines ordered from New Brunswick Scientific. 'NBS' personnel will be in-house June 29 to complete setup and inspection of the equipment.
Copyright 2011 Nano
June 22, 2010: Collaboration With University of Texas Medical Center

Our collaboration with the Texas Medical Center has produced preliminary culture-based results for the rapid detection of Group-B Streptococcus of between 4-6 hours. The initial results are 12-18 times faster than the 72 hour wait time experienced with traditional petri technology. The Texas Medical Center is continuing to finalize these Group-B Strep results and NanoLogix is furnishing additional test kits for that purpose.

In addition, the physicians at the Medical Center will begin testing NanoLogix BNF/BNP™technologies with the drug-resistant ‘superbug’ MRSA (methicillin resistant Staphylococcus aureus). MRSA is a type of staph infection that is the top cause of infections in hospitals. It traditionally takes 1-3 days to detect MRSA. Physicians at the Texas Medical Center anticipate that the NanoLogix technologies will dramatically reduce wait times for the detection of MRSA similar to the results evidenced by their recent test times for Group-B Strep.
May 20, 2010: Negotiations to purchase corporate headquarters
May 12, 2010: NanoLogix has received and installed the first two machines of the twelve ordered from New Brunswick Scientific. We anticipate the balance of the equipment ordered to arrive in May or June. This brings the total machines installed in the production clean room to six, equaling three complete workstations.
April 23, 2010: This week the company ordered new equipment from New Brunswick Scientific. This order is for six MP-1000 Automated Plate Pourers and six MM9 MediaMatic Sterilizers. This equipment will add six workstations to the existing Hubbard, Ohio cleanroom production facility.
April 13, 2010: On 12 April it came to the attention of NanoLogix management that there has been a statement released by an organization called The Street Alert (TSA), purportedly paid for by an organization named D3 Communications LLC, advising readers to take notice of our stock. Neither management, known affiliates, nor employees of NanoLogix have had any dealings whatsoever with either of these two entities.
April 9, 2010:The company announces that it is adding two microbiologists and an additional lab tech to their Research and Development facility in Cincinnati at Bio/Start. NanoLogix is also moving their current R&D to larger labs within the Bio/Start facility in order to accommodate up to eight research personnel for the foreseeable future.
April 8, 2010:After meetings in Houston, Texas, NanoLogix would like to announce that it is expanding its involvement with physicians at the Texas Medical Center significantly beyond that which has been ongoing since September of 2009. This work has been focused on providing early detection of infectious disease. Further details will be released in the near future.
March 26, 2010: The company would like to announce that it has completed construction of its cleanroom production facility. Completion was delayed from the original date by the decision to add an additional cleanroom thereby increasing the potential work stations from thirty-four to fifty-six. Over the next two weeks the company will be performing extensive cleaning of the facility, test runs on the two existing work stations, system tests, and preparing for the installation of additional New Brunswick Scientific equipment currently under order.
January 31, 2010: Items of Interest

CEO Bret Barnhizer and Director John Chatterton have just returned from a week-long trip to the Middle Eastern countries of Kuwait and the UAE. In Kuwait they were hosted as guests of Dr. Eyad Al Saleh, CEO of the Advanced Medical German Company (AMGKWT), an operator of medical laboratories in the country. While in Kuwait, Barnhizer and Chatterton met with various officials. During their visit they toured the Royale Hayat Hospital and five laboratories owned and operated by AMGKWT.

Following their Kuwait visit they traveled to Dubai, United Arab Emirates, where they attended Arab Health 2010 at the Dubai International Exhibition Center, again at the invitation of AMGKWT. The overall purpose of the trip was to assess the market potential for BNP and other NanoLogix products in the Middle East region, with the initial distribution focus to be on the Gulf Cooperation Council (GCC) states.
2009 Updates

November 25, 2009: Calendar of Events

NanoLogix wishes to extend an invitation to interested parties to visit with company science staff and management at the 8th Annual ASM BioDefense Meeting to be held at the Baltimore Marriott Waterfront Hotel, Baltimore, Maryland from Sunday, February 21 to Wednesday, February 24, 2010. NanoLogix personnel can be visited at booth number 29. NanoLogix BNP/BNF™ and BNC technology will be on display. Information about the meeting can be accessed here and the floor plan of the exhibition can be viewed here.

The Company also wishes to extend an invitation to interested parties to visit us at booth number 1313 at the ASM 110th Annual General Meeting to be held in San Diego, California from Sunday, May 23 to Thursday, May 27, 2010. Details of the General Meeting can be accessed here.
October 12, 2009: See our latest article: "NanoLogix Looks to Change How Lab Tests Are Done" in the Youngstown Vindicator's Business Section.
October 6, 2009: Operations Update

NanoLogix is in the process of redirecting the Company’s primary focus from research and development to manufacturing. We have begun preparations for construction of a manufacturing facility to produce our BNP Rapid Detection Kits. Production operations will take place at the company's headquarters in Hubbard, Ohio, where we are negotiating the construction and build-out of existing leased footage in addition to possible expansion of our lease area. We are awaiting quotes from providers of modular clean-rooms for finalization of the production area design. The Company has chosen New Brunswick Scientific’s MP-1000 PourMatic® and associated equipment for use in the BNP kit production process. Production with the selected equipment is scalable to 48,000 kits per week, a capability that should enable us to meet the initial needs of a select group of customers and achieve our short term revenue goals.

Ongoing testing conducted by both NanoLogix and their clients has confirmed that the BNP Rapid Test Kit technology has determined the viability of all micro-organisms tested to date in time spans that are 100 to 400 per cent faster than any competing technologies.
September 22, 2009: NanoLogix Inc. Confirms Date of Shareholder Meeting, Provides Operations Update

NanoLogix announces the date of September 25, 2009 for the Annual Shareholder Meeting. The meeting will be held at the Holiday Inn - Youngstown South, 7410 South Avenue at US 224, Boardman, OH 44512 from the hours of 1pm to 4pm EST.

Shareholder information proxy materials will be sent to those who are shareholders of record as of August 28, 2009. The Company would also like to announce it has recently filed for a patent application for rapid detection of TB.
August 17, 2009: Announcement of 2009 Shareholder’s Meeting

NanoLogix announces the date of September 25, 2009 for the Annual Shareholder Meeting. The meeting will be held at the Holiday Inn - Youngstown South, 7410 South Avenue at US 224, Boardman, OH 44512 from the hours of 1pm to 4pm EST. Shareholder information proxy materials will be sent to those who are shareholders of record as of August 28, 2009.

The Company would also like to announce it has recently filed for a patent application for rapid detection of TB.
July 27, 2009: Technology Breakthrough, Shipment Of Test Kits To Africa and Retainment of Patent Rights

During ongoing work performed on development of a water-quality testing kit for a US Government Agency, recent company research has indicated that NanoLogix's BNP™ and BNC™ test kits may be used for detection and identification of viruses when combined with antibody-coated magnetic particles. This is potentially a major breakthrough for the company's diagnostic technology, going beyond the established capability for bacterial, spore, and mold detection, thereby adding significantly to the battery of detection capabilities currently available with BNP and BNC technology. NanoLogix plans to contract with an Ohio-based research center with BSL-3 virology capabilities to perform further research.

This week the company will ship 500 diagnostic test kits to an international public health organization in Africa. This will be the first use of NanoLogix technology in Africa.

NanoLogix is currently proceeding with national patent filings for BNP technology in China, Japan, India, Brazil, the EU, and Russia. These filings are a progression from the initial PCT (Patent Cooperation Treaty) filing done in 2007.

Construction of the company's production clean room is projected to be completed in late August, with equipment installation to follow.

The company has regained full rights to 18 of its patents licensed to Nutra Pharma after Nutra Pharma's default on their 2008 royalty payment balance. NanoLogix plans to develop the technology to add to the company's diagnostic kit portfolio.

September 18th has been set as the tentative date for the 2009 NanoLogix shareholder meeting. Details will follow in the near future.
July 06, 2009: Operations update and items of interest

During ongoing work performed on development of a water-quality testing kit for a US Government Agency, recent company research has indicated that NanoLogix's BNP™ and BNC™ test kits may be used for detection and identification of viruses when combined with antibody-coated magnetic particles. This is potentially a major breakthrough for the company's diagnostic technology, going beyond the established capability for bacterial, spore, and mold detection, thereby adding significantly to the battery of detection capabilities currently available with BNP and BNC technology. NanoLogix plans to contract with an Ohio-based research center with BSL-3 virology capabilities to perform further research.

This week the company will ship 500 diagnostic test kits to an international public health organization in Africa. This will be the first use of NanoLogix technology in Africa.

NanoLogix is currently proceeding with national patent filings for BNP technology in China, Japan, India, Brazil, the EU, and Russia. These filings are a progression from the initial PCT (Patent Cooperation Treaty) filing done in 2007.

Construction of the company's production clean room is projected to be completed in late August, with equipment installation to follow.

The company has regained full rights to 18 of its patents licensed to Nutra Pharma after Nutra Pharma's default on their 2008 royalty payment balance. NanoLogix plans to develop the technology to add to the company's diagnostic kit portfolio.

September 18th has been set as the tentative date for the 2009 NanoLogix shareholder meeting. Details will follow in the near future.
June 18, 2009: ASM and Operations Update

NanoLogix attended the American Society for Microbiology 109th General Meeting from May 18 – 20, 2009 in Philadelphia, PA. There was tremendous interest in the company's BNP™technology from corporations involved in diagnostic testing, the pharmaceutical industry, governmental agencies, medical laboratories, environmental organizations, and universities. The BNP™ kits are currently undergoing evaluation by a number of those who demonstrated interest.

Construction of a clean room production facility at our Hubbard, Ohio headquarters is ongoing. Upon completion, BNP kit production will be shifted from our Cincinnati lab to the new facility, with BNP kit production anticipated to begin this summer.
April 20, 2009: NanoLogix Begins Construction of Production Facility for Medical Test Kits
March 17, 2009: Operations Update - American Society for Microbiology (ASM) Meeting